Dieter Schiegg

Statistics

Publications

Citations

138

H-Index

Active since

2020

Affiliations

Molecular Partners (Switzerland)(Current)

Spiez Laboratory

Thermo Fisher Scientific (Netherlands)

Utrecht University

University of Lausanne

Dieter Schiegg is an author at Molecular Partners (Switzerland) specializing in sars-cov-2 antiviral therapy, infectious diseases, and molecular virology.

ORCID

Publications per year

2020–2024

Publications

The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants

Sylvia Rothenberger, Daniel L. Hurdiss, Marcel Walser et al. · Nature Biotechnology · 2022 · 60 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +15

Highly potent anti-SARS-CoV-2 multivalent DARPin therapeutic candidates

Marcel Walser, Sylvia Rothenberger, Daniel L. Hurdiss et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2020 · 35 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +16

Ensovibep, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants

Sylvia Rothenberger, Daniel L. Hurdiss, Marcel Walser et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2021 · 18 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell–Mediated Killing of AML Leukemic Stem Cells

Matteo Bianchi, Christian Reichen, Amelie Croset et al. · Cancer Immunology Research · 2024 · 13 citations · Full text

Medicine, Immunology, Oncology +16

Profound Functional Suppression of Tumor‐Infiltrating T‐Cells in Ovarian Cancer Patients Can Be Reversed Using PD‐1‐Blocking Antibodies or DARPin® Proteins

Charlotte Klynning, Esther Schoutrop, Judith M. Förster et al. · Journal of Immunology Research · 2020 · 12 citations · Full text

Medicine, Immunology, Oncology +17

1–5 of 5